Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2017

19.01.2017 | Clinical Study

18F-FET PET prior to recurrent high-grade glioma re-irradiation—additional prognostic value of dynamic time-to-peak analysis and early static summation images?

verfasst von: Daniel F. Fleischmann, Marcus Unterrainer, Peter Bartenstein, Claus Belka, Nathalie L. Albert, Maximilian Niyazi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Most high-grade gliomas (HGG) recur after initial multimodal therapy and re-irradiation (Re-RT) has been shown to be a valuable re-treatment option in selected patients. We evaluated the prognostic value of dynamic time-to-peak analysis and early static summation images in O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET for patients treated with Re-RT ± concomitant bevacizumab. We retrospectively analyzed 72 patients suffering from recurrent HGG with 18F-FET PET prior to Re-RT. PET analysis revealed the maximal tumor-to-background-ratio (TBRmax), the biological tumor volume, the number of PET-foci and pattern of time-activity-curves (TACs; increasing vs. decreasing). Furthermore, the novel PET parameters early TBRmax (at 5–15 min post-injection) and minimal time-to-peak (TTPmin) were evaluated. Additional analysis was performed for gender, age, KPS, O6-methylguanine-DNA methyltransferase methylation status, isocitrate dehydrogenase 1 mutational status, WHO grade and concomitant bevacizumab therapy. The influence of PET and clinical parameters on post-recurrence survival (PRS) was investigated. Shorter TTPmin was related to shorter PRS after Re-RT with 6 months for TTPmin < 12.5 min, 7 months for TTPmin 12.5–25 min and 11 months for TTPmin >25 min (p = 0.027). TTPmin had a significant impact on PRS both on univariate (p = 0.027; continuous) and multivariate analysis (p = 0.011; continuous). Other factors significantly related to PRS on multivariate analysis were increasing vs. decreasing TACs (p = 0.008) and Karnofsky Performance Score (p = 0.015; <70 vs. ≥70). Early TBRmax as well as the other conventional PET parameters were not significantly related to PRS on univariate analysis. Dynamic 18F-FET PET with TTPmin provides a high prognostic value for recurrent HGG prior to Re-RT, whereas early TBRmax does not. Dynamic 18F-FET PET using TTPmin might help to personalize Re-RT treatment regimens in future through voxelwise TTPmin analysis for dose painting purposes and PET-guided dose escalation.
Literatur
1.
Zurück zum Zitat Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi:10.1016/s1470-2045(09)70025-7 CrossRefPubMed Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi:10.​1016/​s1470-2045(09)70025-7 CrossRefPubMed
2.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330 CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.​1056/​NEJMoa043330 CrossRefPubMed
4.
Zurück zum Zitat Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth F-W, Tonn J-C, Belka C (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98:1–14CrossRefPubMed Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth F-W, Tonn J-C, Belka C (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98:1–14CrossRefPubMed
5.
Zurück zum Zitat Flieger M, Ganswindt U, Schwarz SB, Kreth F-W, Tonn J-C, la Fougère C, Ertl L, Linn J, Herrlinger U, Belka C (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117:337–345CrossRefPubMed Flieger M, Ganswindt U, Schwarz SB, Kreth F-W, Tonn J-C, la Fougère C, Ertl L, Linn J, Herrlinger U, Belka C (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117:337–345CrossRefPubMed
6.
Zurück zum Zitat Hundsberger T, Brügge D, Putora PM, Weder P, Weber J, Plasswilm L (2013) Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 112:133–139CrossRefPubMed Hundsberger T, Brügge D, Putora PM, Weder P, Weber J, Plasswilm L (2013) Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 112:133–139CrossRefPubMed
8.
Zurück zum Zitat Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A (2013) Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19:5146–5157CrossRefPubMed Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A (2013) Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19:5146–5157CrossRefPubMed
9.
Zurück zum Zitat Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331 CrossRefPubMed Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.​1056/​NEJMoa043331 CrossRefPubMed
10.
Zurück zum Zitat Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177–183CrossRefPubMed Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177–183CrossRefPubMed
11.
Zurück zum Zitat Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM (2012) 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 14:1079–1089. doi:10.1093/neuonc/nos141 CrossRefPubMedPubMedCentral Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM (2012) 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 14:1079–1089. doi:10.​1093/​neuonc/​nos141 CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W (2012) 3′-deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53:29–36. doi:10.2967/jnumed.111.092387 CrossRefPubMed Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W (2012) 3′-deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53:29–36. doi:10.​2967/​jnumed.​111.​092387 CrossRefPubMed
13.
Zurück zum Zitat Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W (2014) Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res 20:3550–3559. doi:10.1158/1078-0432.ccr-13-1440 CrossRefPubMedPubMedCentral Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W (2014) Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res 20:3550–3559. doi:10.​1158/​1078-0432.​ccr-13-1440 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Harris RJ, Cloughesy TF, Hardy AJ, Liau LM, Pope WB, Nghiemphu PL, Lai A, Ellingson BM (2015) MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol 122:497–505. doi:10.1007/s11060-015-1755-8 CrossRefPubMed Harris RJ, Cloughesy TF, Hardy AJ, Liau LM, Pope WB, Nghiemphu PL, Lai A, Ellingson BM (2015) MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol 122:497–505. doi:10.​1007/​s11060-015-1755-8 CrossRefPubMed
15.
Zurück zum Zitat Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY (2016) The Impact of T2/FLAIR evaluation per RANO criteria on Response assessment of recurrent glioblastoma patients treated with bevacizumab. Clin Cancer Res 22:575–581. doi:10.1158/1078-0432.ccr-14-3040 CrossRefPubMed Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY (2016) The Impact of T2/FLAIR evaluation per RANO criteria on Response assessment of recurrent glioblastoma patients treated with bevacizumab. Clin Cancer Res 22:575–581. doi:10.​1158/​1078-0432.​ccr-14-3040 CrossRefPubMed
16.
Zurück zum Zitat Leu K, Enzmann DR, Woodworth DC, Harris RJ, Tran AN, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM (2014) Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging 14:31. doi:10.1186/s40644-014-0031-z CrossRefPubMedPubMedCentral Leu K, Enzmann DR, Woodworth DC, Harris RJ, Tran AN, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM (2014) Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging 14:31. doi:10.​1186/​s40644-014-0031-z CrossRefPubMedPubMedCentral
17.
18.
Zurück zum Zitat Piroth M, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, Kaiser H, Langen K, Eble M (2009) Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme: a dosimetric comparison. Radiat Oncol 4:57CrossRefPubMedPubMedCentral Piroth M, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, Kaiser H, Langen K, Eble M (2009) Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme: a dosimetric comparison. Radiat Oncol 4:57CrossRefPubMedPubMedCentral
19.
20.
Zurück zum Zitat Miwa K, Matsuo M, Ogawa S, Shinoda J, Yokoyama K, Yamada J, Yano H, Iwama T (2014) Re-irradiation of recurrent glioblastoma multiforme using 11 C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. Radiat Oncol 9: 181 doi:10.1186/1748-717x-9-181 CrossRefPubMedPubMedCentral Miwa K, Matsuo M, Ogawa S, Shinoda J, Yokoyama K, Yamada J, Yano H, Iwama T (2014) Re-irradiation of recurrent glioblastoma multiforme using 11 C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. Radiat Oncol 9: 181 doi:10.​1186/​1748-717x-9-181 CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Albert NL, Winkelmann I, Suchorska B, Wenter V, Schmid-Tannwald C, Mille E, Todica A, Brendel M, Tonn JC, Bartenstein P, la Fougere C (2016) Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging 43:1105–1114. doi:10.1007/s00259-015-3276-2 CrossRefPubMed Albert NL, Winkelmann I, Suchorska B, Wenter V, Schmid-Tannwald C, Mille E, Todica A, Brendel M, Tonn JC, Bartenstein P, la Fougere C (2016) Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging 43:1105–1114. doi:10.​1007/​s00259-015-3276-2 CrossRefPubMed
22.
Zurück zum Zitat Niyazi M, Jansen N, Ganswindt U, Schwarz S, Geisler J, Schnell O, Büsing K, Eigenbrod S, la Fougère C, Belka C (2012) Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET–PET. J Neurooncol 110:389–395. doi:10.1007/s11060-012-0980-7 CrossRefPubMed Niyazi M, Jansen N, Ganswindt U, Schwarz S, Geisler J, Schnell O, Büsing K, Eigenbrod S, la Fougère C, Belka C (2012) Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET–PET. J Neurooncol 110:389–395. doi:10.​1007/​s11060-012-0980-7 CrossRefPubMed
23.
Zurück zum Zitat Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, Niyazi M, Tonn J-C, Bartenstein P, Kreth F-W, la Fougère C (2015) Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med 56:9–15. doi:10.2967/jnumed.114.144675 CrossRefPubMed Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, Niyazi M, Tonn J-C, Bartenstein P, Kreth F-W, la Fougère C (2015) Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med 56:9–15. doi:10.​2967/​jnumed.​114.​144675 CrossRefPubMed
25.
Zurück zum Zitat Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G (2011) O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52:856–864. doi:10.2967/jnumed.110.086645 CrossRefPubMed Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G (2011) O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52:856–864. doi:10.​2967/​jnumed.​110.​086645 CrossRefPubMed
26.
Zurück zum Zitat Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, Sabel M, Langen KJ (2013) Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 40:22–33. doi:10.1007/s00259-012-2251-4 CrossRefPubMed Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, Sabel M, Langen KJ (2013) Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 40:22–33. doi:10.​1007/​s00259-012-2251-4 CrossRefPubMed
27.
Zurück zum Zitat Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. doi:10.1200/jco.2009.26.3541 CrossRefPubMed Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. doi:10.​1200/​jco.​2009.​26.​3541 CrossRefPubMed
28.
Zurück zum Zitat Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn J-C, Kreth FW (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39:1021–1029CrossRefPubMed Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn J-C, Kreth FW (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39:1021–1029CrossRefPubMed
29.
Zurück zum Zitat Mehrkens J, Pöpperl G, Rachinger W, Herms J, Seelos K, Tatsch K, Tonn J, Kreth F (2008) The positive predictive value of O-(2-[18F] fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 88:27–35CrossRefPubMed Mehrkens J, Pöpperl G, Rachinger W, Herms J, Seelos K, Tatsch K, Tonn J, Kreth F (2008) The positive predictive value of O-(2-[18F] fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 88:27–35CrossRefPubMed
30.
Zurück zum Zitat Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, Simon M, Popperl G, Kreth FW, la Fougere C, Weller M, Tonn JC (2015) Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 84:710–719. doi:10.1212/wnl.0000000000001262 CrossRefPubMed Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, Simon M, Popperl G, Kreth FW, la Fougere C, Weller M, Tonn JC (2015) Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 84:710–719. doi:10.​1212/​wnl.​0000000000001262​ CrossRefPubMed
31.
Zurück zum Zitat Niyazi M, Ganswindt U, Schwarz SB, Kreth F-W, Tonn J-C, Geisler J, la Fougère C, Ertl L, Linn J, Siefert A (2012) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82:67–76CrossRefPubMed Niyazi M, Ganswindt U, Schwarz SB, Kreth F-W, Tonn J-C, Geisler J, la Fougère C, Ertl L, Linn J, Siefert A (2012) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82:67–76CrossRefPubMed
32.
Zurück zum Zitat Jager PL, Vaalburg W, Pruim J, de Vries EGE, Langen K-J, Piers DA (2001) Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42:432–445PubMed Jager PL, Vaalburg W, Pruim J, de Vries EGE, Langen K-J, Piers DA (2001) Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42:432–445PubMed
33.
Zurück zum Zitat Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Göbel G, la Fougère C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G (2013) [18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol 15:341–351. doi:10.1093/neuonc/nos300 CrossRefPubMedPubMedCentral Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Göbel G, la Fougère C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G (2013) [18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol 15:341–351. doi:10.​1093/​neuonc/​nos300 CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ (2011) Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 99:218–224. doi:10.1016/j.radonc.2011.03.006 CrossRefPubMed Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ (2011) Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 99:218–224. doi:10.​1016/​j.​radonc.​2011.​03.​006 CrossRefPubMed
Metadaten
Titel
18F-FET PET prior to recurrent high-grade glioma re-irradiation—additional prognostic value of dynamic time-to-peak analysis and early static summation images?
verfasst von
Daniel F. Fleischmann
Marcus Unterrainer
Peter Bartenstein
Claus Belka
Nathalie L. Albert
Maximilian Niyazi
Publikationsdatum
19.01.2017
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-016-2366-8

Weitere Artikel der Ausgabe 2/2017

Journal of Neuro-Oncology 2/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.